At least 16 biotechs and pharmas reported earnings last week. ViroPharma Inc. (NASDAQ:VPHM) ended the week up 21%, adding nearly $300 million to its valuation, despite missing the Street's revenue and EPS estimates. The company, which has been facing generic competition for its oral antibiotic Vancocin vancomycin, raised its 2012 guidance for Cinryze complement 1 (C1) esterase to treat hereditary angioedema (HAE) to $320-$335 million from $310-$330 million. ViroPharma gained 14% on Monday, prior to the Thursday earnings release, after FDA approved an industrial scale Cinryze manufacturing facility. Cancer diagnostic company Genomic Health Inc. (NASDAQ:GHDX) was up 11% on the week after beating the Street's revenue and EPS estimates and providing 2012 revenue guidance of $230-$240 million. Conversely, specialty pharma Santarus Inc. (NASDAQ:SNTS) closed down 15% on the week after missing the Street's revenue and EPS projections. Also last week, Santarus partner Cosmo Pharmaceuticals S.p.A. (SIX:COPN) said the Netherlands Medicines Evaluation Board (MEB) decided not to approve an MAA for Cortiment budesonide to treat active, mild to moderate ulcerative colitis. Santarus expects an FDA decision on the U.S. application in mid-October (see B12). Mcap in $M

Company

2Q12 EPS est

2Q12 EPS actual

Outcome

Growth from 2Q11

8/10 cls

Wk chg

% chg

Mcap chg

8/10 Mcap

Bio-Rad Laboratories Inc. (NYSE:BIO)

$1.19

$1.69

Beat by $0.50

20%

$103.11

$6.53

7%

$184.5

$2,912.9

2Q12 revenues were up 3% to $510.4M from $521.7M in 2Q11. The Street was expecting $524.6M. In the clinical diagnostics segment, sales were up 5% to $344M, while the life science segment sales decreased 1% to $162.4M. SG&A declined by 8% to $162.3M. Percent changes assume constant currency.

BioSpecifics Technologies Corp. (NASDAQ:BSTC)

$0.07

$0.10

Beat by $0.03

-72%

$18.09

-$0.42

-2%

-$2.7

$114.6

2Q12 revenues fell 48% to $2.6M from $5M in 2Q11 The Street was expecting $2.5M. In 2Q11, BioSpecifics recognized $2.6M of the $30M milestone payment to Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL) from Pfizer Inc. (NYSE:PFE) following the launch of Dupuytren's contracture drug Xiapex collagenase clostridium in the EU. Pfizer has EU rights from Auxilium, which has worldwide rights from BioSpecifics.